Compliagence.ai Helps Organizations Map the Compliance Landscape, Close Gaps and Design Operations to be Always-Compliant

SAN FRANCISCO, April 29, 2026 /PRNewswire/ — Compliagence, the compliance company for the AI era, today announced the global availability of its flagship AI-native compliance platform, Compliagence.ai. The Compliagence.ai platform is built on the experience of 30+year Compliance and Cybersecurity veterans from Fortune 500 companies and Big Four firms. While other products focus on collecting evidence, Compliagence.ai helps companies understand regulations and apply operational design that will keep them perpetually audit-ready and compliant across industries.

Each day, 230+ new regulations and industry standards are issued worldwide. AI is only accelerating the regulation pace, and fines for non-compliance hit a record $19 billion in 2024. Given the complexity of a rapidly changing compliance landscape, organizations need ongoing regulatory monitoring and intelligence, gap analysis and controls design in a single platform. 

“After 30+ years in compliance, I’ve learned that the hardest part isn’t passing the audit. It’s the work that happens before the auditor ever shows up,” said Brenda Bernal, Founder and CEO of Compliagence. “Compliance teams spend 90% of their time understanding what global regulations and industry standards apply, figuring out the gaps, and designing operational controls that close those gaps. Most tools offer little help with these tasks. That’s why we built Compliagence.ai to give companies the confidence that they are always compliant and ready.”

AI Scale with Human-in-the-Loop 

The Compliagence.ai platform offers regulatory and industry standard intelligence using both AI and humans-in-the- loop who understand compliance in context. Compliagence offers three subscription levels:

Essential: Monitor global and regional-specific changes to understand how they impact the organization’s compliance posture, reducing manual research and reactive compliance efforts. Research that used to take days can now be done in minutes.Standard: Perform quick and comprehensive company-wide gap analyses and identify exposure to non-compliance fines and other risks. Continuous intelligence provides confidence around current regulatory compliance.Premium: Create a customized action plan for compliance gaps and build compliance into the entire organizational design. The platform provides a living audit trail where every decision is documented and the intelligence stays, even when employees leave.

Compliance-forward companies are taking notice. Victoria Hu is the CEO of Tied AI, an AI platform that predicts long-term outcomes for key hires, core partnerships, and strategic investments. Tied AI is an early user of the Compliagence.ai platform for regulatory intelligence. “The most expensive question in business isn’t what to build, but who to trust,” said Hu. “That’s why larger corporations have rigid processes for vendor approvals. If you can’t get certified and prove you are compliant, you will lose deals. To actually get compliance right, you need to partner with people who are industry experts.”

“The Compliagence team has been in the trenches with big, global companies, gotten the battle scars and emerged with the map,” Hu continued. “The sheer weight of their experience is reassuring. As we grow, we know that we have a partner we can trust in Compliagence.”

Trusted Security and Governance

Compliagence adheres to industry-leading security, risk management, and responsible AI practices.

The platform includes:

Data privacy and security controls aligned with ISO/IEC 27001 and 42001Human-in-the-loop oversight to ensure accuracy and qualityContinuous monitoring to improve model performanceTransparent outputs so teams can verify the reasoning behind every recommendation

Availability

The Compliagence platform is available worldwide as of April 21, 2026. To learn more or subscribe, visit compliagence.ai.

About Compliagence
Compliagence provides the compliance platform for the AI-era. Compliagence.ai, the AI-native compliance platform, was built to help organizations keep pace with rapidly evolving regulations and compliance obligations. Founded in 2025 and based in San Mateo County, Compliagence provides regulatory intelligence, gap assessment, and controls design in a single integrated platform. Learn more at compliagence.ai.

Contact:

Jane Gideon
415-682-9292
413198@email4pr.com

View original content:https://www.prnewswire.com/news-releases/compliagence-announces-global-availability-of-compliagenceai-the-platform-designed-by-compliance-and-cybersecurity-veterans-302757207.html

SOURCE Compliagence.ai

Axtria’s pharma-native AgentOps framework and LangChain’s leading agent development platform help life sciences enterprises deploy AI agents with confidence and turn experimentation into operational results

BERKELEY HEIGHTS, N.J., April 29, 2026 /PRNewswire/ — Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced a strategic partnership with LangChain,  the company behind the industry-standard LangSmith platform for building, deploying, and observing AI agents at scale. Together, the two organizations will help life sciences enterprises turn agentic AI experiments into operational results in production.

The partnership centers on Axtria’s AgentOps framework, a pharma-native governance layer built on LangSmith, providing enterprise clients with the visibility, compliance controls, and evaluation rigor to responsibly scale AI agents in regulated environments. The framework is already in production at a leading global biopharma delivering measurable gains in agent observability, evaluation quality, and governance compliance and is live across Axtria’s own InsightsMAx.ai multi-agent platform

LangSmith delivers the foundational infrastructure: building deep long-horizon agents, end-to-end agent tracing, prompt management, agent evaluation and deployments tooling. Axtria adds the pharma intelligence layer including Look-Alike, Sound-Alike (LASA) drug safety evaluators to prevent dangerous medication confusions, GxP compliance enforcement, patient safety detection, and persona-driven dashboards for Medical Affairs, Medical Legal Review, Commercial, and IT stakeholders.

What This Means for Life Sciences Organizations

Most pharma and biotech companies have AI agent pilots underway. Few have crossed the threshold into reliable, governed production. Two challenges consistently block the path: regulated environments demand a level of traceability and compliance that generic AI tooling does not provide, and the domain expertise required to define ‘good’ for a medical affairs agent is fundamentally different from a commercial or compliance one. This partnership directly addresses both.

Commercial: Field Agents That Actually Get Used: Pre-call planning agents surface HCP insights and next-best-action recommendations ahead of every rep interaction. The solution tracks not just what the agent recommends but whether reps act on it. Performance is continuously tuned on real field feedback, creating a direct, measurable link between agent output and commercial results.

Medical Affairs: From Query to Defensible Answer: When a Medical Affairs team deploys an oncology agent to answer HCP queries, every response is automatically checked for drug name confusion, validated against approved labeling, and fully traceable. If a regulator asks how the system reached a conclusion, the complete decision path is on record. No retroactive documentation. No manual reconstruction.

Medical Legal Review: Compliance Built In, Not Bolted On: Promotional content is pre-screened against FDA-approved labeling before it ever reaches a human reviewer — claims validated, off-label risks flagged, fair balance checked. The audit trail isn’t assembled after the fact. It’s a byproduct of how the agent works.

“Axtria has spent more than 15 years helping the world’s leading life sciences companies turn data into decisions, and AI agents are the next frontier of that mission. Our clients are past the question of whether agents can work they’re asking how to make them work reliably across the enterprise and tie that performance to real results. This partnership with LangChain gives them exactly that: the governance foundation, the operational playbook, and the agent capabilities to move from experimentation to enterprise scale without starting from scratch,” Navdeep (Navi) Chadha, Co-founder & EVP, Axtria.

“We know what AI agents can do, but the true value for the enterprise is in how reliably, safely, and transparently they do it. Axtria brings exactly the domain depth and operational rigor that life sciences organizations need to move from experimentation to production-grade AI. Together, we’re giving pharma companies a clear path from agent deployment to real, defensible business outcomes,” Karan Singh, Head of Partnerships, LangChain.

What the Partnership Delivers

Together, Axtria and LangChain offer life sciences organizations an integrated, enterprise-ready solution spanning the full agentic AI lifecycle:

Agents as a Service: Pre-built, pharma-validated agents across Commercial, Medical Affairs, Patient Services, and Data Engineering deployable and governed from day one, without building from scratch.Pharma-Native Observability & Governance: Enterprise-grade visibility, compliance enforcement, and audit-readiness built specifically for regulated environments covering GxP traceability, immutable audit trails, and model version tracking.Cost Intelligence: Portfolio-level cost governance that helps enterprises optimize AI spend, right-size model selection, and prevent runaway costs without compromising safety or quality.

Learn More

Life sciences organizations interested in moving their AI agent programs from pilot to production can request a demo at connect@axtria.com.  

About Axtria 

Axtria helps life sciences companies harness the potential of data science and software to improve patient outcomes by connecting the right therapies to the right patients at the right time. A leading global provider of award-winning cloud software and data analytics, Axtria delivers proven solutions that help pharmaceutical, medical device, and diagnostics companies complete their journey from data to insights to action. As a participant in the United Nations Global Compact, Axtria is committed to aligning strategies and operations with universal principles on human rights, labor, environment, and anti-corruption. For more information, visit www.axtria.com. 

About LangChain

LangChain is the agent engineering platform powering top engineering teams, from AI startups to global enterprises. Its open-source frameworks, including LangChain, LangGraph, and Deep Agents, have surpassed 1 billion cumulative downloads and are used by over one million practitioners. LangSmith, the observability, evaluation, and deployment platform, serves over 300 enterprise customers and 5 of the Fortune 10. LangChain is backed by Sequoia Capital, Benchmark, and IVP. For more information, visit langchain.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/from-pilot-to-production-axtria-and-langchain-partner-to-govern-and-scale-ai-agents-in-pharma-302757028.html

SOURCE Axtria, Inc.

BLOOMINGTON, Minn., April 29, 2026 /PRNewswire/ — R3 Continuum today announced the expansion of its senior clinical leadership team with the appointments of David Wright, Psy.D., as Senior Vice President of Clinical Strategy, and Maria Whitter, MSW, LCSW, CEAP, SAP, as Vice President of Clinical Services. These appointments underscore R3’s continued investment in clinical excellence, innovation, and scalable growth as demand for high-impact workplace behavioral health solutions continues to accelerate.

In his role, Dr. Wright will lead R3’s clinical market strategy, guide the development of differentiated service models, and serve as a primary clinical voice to employers, brokers, consultants, and industry partners. He brings more than two decades of experience spanning workplace behavioral health strategy, enterprise program leadership, and market-facing innovation, including senior leadership roles at Headspace, meQuilibrium, and Anthem. Widely respected for blending clinical depth with commercial insight, Dr. Wright will play a key role in strengthening R3’s market leadership and growth trajectory.

Whitter will oversee enterprise clinical operations, advance R3’s clinical delivery strategy, strengthen data-informed quality oversight, and ensure consistent, high-quality care across R3’s national footprint. She brings more than 20 years of behavioral health leadership experience across clinical operations, workplace wellbeing, regulatory compliance, crisis response, and program innovation, with prior leadership roles at Optum, Centene, and Magellan Health. Known for building high-performing teams and scalable, evidence-based programs, Whitter will focus on operationalizing excellence as R3 continues to expand.

Together, Wright and Whitter will partner closely across operations, data, technology, strategy, and client teams to ensure R3 delivers measurable outcomes, clinical credibility, and differentiated value at scale.

“As R3 continues to grow, it’s critical that our leadership structure evolves alongside our ambition,” said Scott T. Alfieri, Chief Executive Officer of R3 Continuum. “David and Maria bring complementary strengths that deepen our clinical foundation while positioning us for the next phase of growth. These appointments reflect our commitment to scaling excellence, strengthening our market impact, and ensuring R3 remains the trusted partner employers rely on for workplace behavioral health.”

About R3 Continuum

R3 Continuum is the leader in specialty workplace behavioral health solutions, helping organizations strengthen resilience, elevate performance, and support the mental wellbeing of their people. Grounded in clinical excellence and driven by measurable impact, R3 delivers the right support at the right moment—helping individuals, teams, and organizations thrive while achieving meaningful business outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/r3-continuum-expands-clinical-leadership-team-to-accelerate-growth-and-market-impact-302756609.html

SOURCE R3 Continuum